Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1995-06-07
1999-09-28
Reeves, Julie
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
5303877, 53038722, 53038873, 5303887, 5303888, 5303896, 5303897, 4241361, 4241381, 4241441, 4241531, 4241551, 4241731, 4241741, 435328, 435330, 435334, 4353431, 435344, 435449, 435 711, A61K 39395, C12N 1506
Patent
active
059590840
ABSTRACT:
This invention relates generally to the field of immunology, in particular that of antibodies and antibody productions. More specifically, this invention relates to bispecific antibodies, the hybrid hybridomas which produce them, the parent hybridomas, the production and selection of the hybridomas and hybrid hybridomas, and the purification of the bispecific antibodies. Specific examples relate to bispecific monoclonal antibodies which recognize both the human multi-drug resistance antigen, P-glycoprotein and human Fc.gamma. receptor III (hFc.gamma.RIII). These bispecific antibodies are useful in killing cancer cells.
REFERENCES:
patent: 4474893 (1984-10-01), Reading
patent: 4676980 (1987-06-01), Segal et al.
Bolhuis et al., "Adoptive Immunotherapy of Ovarian Carcinoma with BS-MAb-Targeted Lymphocytes: A Multicenter Study," Int. J. Cancer: Supplement 7:78-81 (1992).
DeLau et al., "Absence of Preferential Homologous H/L Chain Association in Hybrid Hybridomas," The Journal of Immunology 146(3):906-914 (1991).
de Palazzo et al., "Antitumor Effects of a Bispecific Antibody Targeting CA19-9 Antigen and CD16," Cancer Research 52:5713-5719 (1992).
Demanet et al., "Bispecific Antibody Therapy of Two Murine B-Cell Lymphomas," Int. J. Cancer Supplement 7:67-68 (1992).
Fanger et al., "Bispecific Antibodies and Targeted Cellular Cytotoxicity," Immunology Today 12(2):51-54 (1991).
Greenman et al., "Comparative Efficiencies of Bispecific F(ab'y) and Chimeric Mouse/Human IgG Antibodies in Recruiting Cellular Effectors for Cytotoxicity Via Fcy Receptors," Cancer Immunol. Immunotherapy 34:361-369 (1992).
Nitta et al., "Preliminary Trial of Specific Targeting Therapy Against Malignant Glioma," The Lancet 35:368-371 (1990).
Karpovsky et al., J. Exp. Med. 160:1686 (1984).
Perez et al., Nature 316:354 (1985).
Ring et al., "Targeted Lysis of Human Breast Cancer Cells by Human Effector Cells Armed With Bispecific Antibody 2B1 (Anti-c-erbB-2/Anti-Fcy Receptor III)," Breast Epithelial Antigens Abstract pp. 91-104 (1991).
Staerz et al., Immunology Today 7:241 (1986).
Staerz et al., Nature 314:628 (1985).
Titus et al., J. Immunol. 138:4018 (1987).
Weiner et al., "A Human Tumor Xenograft Model of Therapy with a Bispecific Monoclonal Antibody Targeting c-erbB-2 and CD16," Cancer Research 53:94-100 (1993).
Weiner, George J., "Bispecific IgG and IL-2 Therapy of a Syngeneic B-Cell Lymphoma in Immunocompetent Mice," Int. J. Cancer: Supplement 7:63-66 (1992).
Unkeless, J. Exp. Med. vol. 150 Sep. 1979 580-596.
Staerz and Bevan, Proc. Natl. Acad. Sci. vol. 83 Mar. 1986 1453-1457.
Titus et. al. Journal of Immunology Nov. 1987 vol. 139(9)3153-3158.
Vandijk et. al. Int. J. Cancer 44 738-743 1989.
Hamada et. al. (cited for interest) PNAS vol. 83 p. 7785 1986.
Waldmann, Science vol. 252 1657. 1991.
Hird et. al. Genes and Cancer 1990 Wiley and Sons Ltd. p. 183.
Houghton et. al. Seminars in Oncology vol. 13 No. 2 1986 165-179.
Harris et. al. TibTech. vol. 11, 1993, p. 42.
Bohuis et al. Int. J. Cancer, 7, 78-81, 1992.
Bonardi et al. Int J. Cancer 7, 73-77, 1992.
Ring David
Shi Tian-Xiang
Blackburn Robert P
Chiron Corporation
Reeves Julie
LandOfFree
Bispecific antibodies, methods of production and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bispecific antibodies, methods of production and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bispecific antibodies, methods of production and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-704681